Comprehensive review of endocannabinoid system targets for treating inflammatory and neuropathic pain
A major review found that cannabinoid receptor agonists and endocannabinoid enzyme inhibitors produce reliable pain relief and offer opioid-sparing effects across preclinical inflammatory and neuropathic pain models, though clinical evidence for enzyme inhibitors remains limited.
Quick Facts
What This Study Found
This comprehensive review examined the entire endocannabinoid system as a source of pain treatment targets, covering CB1 and CB2 receptors plus the enzymes that make and break down endocannabinoids (FAAH and MAGL).
In preclinical models, cannabinoid receptor agonists and inhibitors of endocannabinoid-regulating enzymes (FAAH and MAGL) produced reliable antinociceptive (pain-reducing) effects across multiple inflammatory and neuropathic pain models.
A particularly notable finding: these compounds offered opioid-sparing effects, meaning they could reduce the amount of opioid medication needed for pain control.
Clinical studies showed that medicinal cannabis or cannabinoid-based medications relieve pain in cancer, multiple sclerosis, and fibromyalgia. However, clinical data had not yet demonstrated analgesic efficacy for FAAH or MAGL inhibitors in human trials.
The gap between strong preclinical results and limited clinical translation for enzyme inhibitors remained a key challenge in the field.
Key Numbers
Key targets: CB1 and CB2 receptors, FAAH enzyme, MAGL enzyme. Clinical efficacy shown for: cancer pain, MS pain, fibromyalgia. Opioid-sparing effects demonstrated in preclinical models.
How They Did This
Comprehensive review of preclinical and clinical evidence on endocannabinoid system targets for pain, covering CB1/CB2 receptor agonists, FAAH inhibitors, and MAGL inhibitors across inflammatory and neuropathic pain models.
Why This Research Matters
The opioid crisis has created urgent need for alternative pain medications. The endocannabinoid system represents a parallel pain-modulating pathway, and the finding that cannabinoid-based approaches can spare opioid use is particularly significant for patients with chronic pain conditions.
The Bigger Picture
This review maps the entire landscape of endocannabinoid pain targets, revealing both mature areas (CB receptor agonists with clinical evidence) and emerging areas (enzyme inhibitors with strong preclinical but limited clinical evidence). The opioid-sparing potential is perhaps the most significant practical implication for current clinical practice.
What This Study Doesn't Tell Us
The gap between preclinical promise and clinical results for enzyme inhibitors is a significant concern. Cannabinoid receptor agonists carry side effect profiles including psychoactive effects. Long-term safety data for many of these approaches remains limited. Not all pain conditions were covered equally.
Questions This Raises
- ?Why have FAAH and MAGL inhibitors failed to translate preclinical success to clinical trials?
- ?Can combination approaches (cannabinoids + low-dose opioids) be formalized into clinical protocols?
- ?Which chronic pain populations benefit most from cannabinoid-based approaches?
Trust & Context
- Key Stat:
- Cannabinoid approaches offer opioid-sparing effects across preclinical pain models
- Evidence Grade:
- This comprehensive review covers extensive preclinical and clinical literature from a high-impact journal (Neuropsychopharmacology), providing strong evidence on the current state of endocannabinoid pain research.
- Study Age:
- Published in 2018. Clinical trials of endocannabinoid enzyme inhibitors have continued since publication, with mixed results.
- Original Title:
- The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.
- Published In:
- Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(1), 52-79 (2018)
- Authors:
- Donvito, Giulia(2), Nass, Sara R(3), Wilkerson, Jenny L(5), Curry, Zachary A, Schurman, Lesley D, Kinsey, Steven G, Lichtman, Aron H
- Database ID:
- RTHC-01646
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabinoids replace opioids for pain?
Not replace entirely, but potentially reduce the amount needed. The review found that endocannabinoid-based approaches offer opioid-sparing effects in preclinical models, meaning they could lower the opioid dose required for adequate pain control.
Why focus on enzymes rather than just THC?
Inhibiting FAAH or MAGL boosts the body's own endocannabinoids at the site of pain rather than flooding the entire brain with a psychoactive compound. This targeted approach could theoretically provide pain relief with fewer side effects.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
- thc-and-painkillers-opioid-interactions
- thc-and-muscle-relaxers-combining
- thc-and-ibuprofen-safe-combine-research
- cannabis-and-arthritis-research
Cite This Study
https://rethinkthc.com/research/RTHC-01646APA
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L; Curry, Zachary A; Schurman, Lesley D; Kinsey, Steven G; Lichtman, Aron H. (2018). The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 43(1), 52-79. https://doi.org/10.1038/npp.2017.204
MLA
Donvito, Giulia, et al. "The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain.." Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2018. https://doi.org/10.1038/npp.2017.204
RethinkTHC
RethinkTHC Research Database. "The Endogenous Cannabinoid System: A Budding Source of Targe..." RTHC-01646. Retrieved from https://rethinkthc.com/research/donvito-2018-the-endogenous-cannabinoid-system
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.